RT Journal Article
SR Electronic
T1 Functional Antibodies in COVID-19 Convalescent Plasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.08.21253157
DO 10.1101/2021.03.08.21253157
A1 Herman, Jonathan D.
A1 Wang, Chuangqi
A1 Loos, Carolin
A1 Yoon, Hyunah
A1 Rivera, Johanna
A1 Dieterle, M. Eugenia
A1 Haslwanter, Denise
A1 Jangra, Rohit K.
A1 Bortz, Robert H.
A1 Bar, Katharine J.
A1 Julg, Boris
A1 Chandran, Kartik
A1 Lauffenburger, Douglas
A1 Pirofski, Liise-anne
A1 Alter, Galit
YR 2021
UL http://medrxiv.org/content/early/2021/03/11/2021.03.08.21253157.abstract
AB In the absence of an effective vaccine or monoclonal therapeutic, transfer of convalescent plasma (CCP) was proposed early in the SARS-CoV-2 pandemic as an easily accessible therapy. However, despite the global excitement around this historically valuable therapeutic approach, results from CCP trials have been mixed and highly debated. Unlike other therapeutic interventions, CCP represents a heterogeneous drug. Each CCP unit is unique and collected from an individual recovered COVID-19 patient, making the interpretation of therapeutic benefit more complicated. While the prevailing view in the field would suggest that it is administration of neutralizing antibodies via CCP that centrally provides therapeutic benefit to newly infected COVID-19 patients, many hospitalized COVID-19 patients already possess neutralizing antibodies. Importantly, the therapeutic benefit of antibodies can extend far beyond their simple ability to bind and block infection, especially related to their ability to interact with the innate immune system. In our work we deeply profiled the SARS-CoV-2-specific Fc-response in CCP donors, along with the recipients prior to and after CCP transfer, revealing striking SARS-CoV-2 specific Fc-heterogeneity across CCP units and their recipients. However, CCP units possessed more functional antibodies than acute COVID-19 patients, that shaped the evolution of COVID-19 patient humoral profiles via distinct immunomodulatory effects that varied by pre-existing SARS-CoV-2 Spike (S)-specific IgG titers in the patients. Our analysis identified surprising influence of both S and Nucleocapsid (N) specific antibody functions not only in direct antiviral activity but also in anti-inflammatory effects. These findings offer insights for more comprehensive interpretation of correlates of immunity in ongoing large scale CCP trials and for the design of next generation therapeutic design.Competing Interest StatementGalit Alter is a founder of SeromYx Systems, Inc.Funding StatementWe thank Nancy Zimmerman, Mark and Lisa Schwartz, an anonymous donor (financial support), Terry and Susan Ragon, and the SAMANA Kay MGH Research Scholars award for their support. We acknowledge support from the Ragon Institute of MGH, MIT and Harvard, the Massachusetts Consortium on Pathogen Readiness (MassCPR), the NIH (3R37AI080289, R01AI146785, R01AI132633, U19AI42790, U19AI135995, U19AI42790, 1U01CA260476, CIVIC75N93019C00052, T32 AI007061), the Gates foundation Global Health Vaccine Accelerator Platform funding (OPP1146996 and INV001650), and the Musk Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham IRB Protocol 2020P003150All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request